Recursion Pharmaceuticals, Inc.
RXRX
$4.94
$0.163.35%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -649.13M | -574.78M | -463.66M | -377.75M | -374.93M |
| Total Depreciation and Amortization | 63.33M | 48.45M | 36.49M | 31.10M | 31.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 164.76M | 141.97M | 103.06M | 81.22M | 71.45M |
| Change in Net Operating Assets | 38.02M | -4.47M | -35.07M | -52.39M | -59.52M |
| Cash from Operations | -383.03M | -388.83M | -359.17M | -317.82M | -331.52M |
| Capital Expenditure | -10.84M | -8.87M | -13.70M | -14.46M | -10.65M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 277.10M | 277.10M | 277.10M | -71.00K | -71.00K |
| Divestitures | -4.44M | -4.44M | -- | -- | -- |
| Other Investing Activities | -4.01M | -4.35M | -3.35M | -3.35M | -2.95M |
| Cash from Investing | 257.82M | 259.44M | 260.06M | -17.89M | -13.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.52M | -6.46M | -4.44M | -3.03M | -770.00K |
| Issuance of Common Stock | 176.81M | 337.21M | 308.56M | 377.17M | 412.21M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.00M | -- | -- | -- | -- |
| Cash from Financing | 165.29M | 330.75M | 304.12M | 374.14M | 411.44M |
| Foreign Exchange rate Adjustments | 11.02M | 1.65M | -3.41M | 190.00K | -328.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.09M | 203.01M | 201.60M | 38.62M | 65.93M |